CAS NO: | 136381-85-6 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptidecholecystokinin (CCK1) receptorantagonist with anEC50of 6 nM and aKiof 0.2 nM. Lintitript displays >33-fold selectivity more selective forCCK1than CCK2 receptors (EC50value of 200 nM). Lintitript increases plasma concentration ofleptinand food intake as well as plasma concentration ofinsulin[1][2][3]. | ||||||||||||||||
IC50& Target | EC50: 6 nM (cholecystokinin (CCK1) receptor)[2]; Ki: 0.2 nM (cholecystokinin (CCK1) receptor)[1] | ||||||||||||||||
体外研究 (In Vitro) | In vitro, Lintitript (SR 27897) is a competitive antagonist of cholecystokinin (CCK)-stimulated amylase release in isolated rat pancreatic acini (pA2= 7.50) and of CCK-induced guinea pig gall bladder contractions (pA2= 9.57)[1]. | ||||||||||||||||
体内研究 (In Vivo) | Lintitript (SR 27897; 1 mg/kg, i.v.) completely reverses the CCK-induced amylase secretion. Lintitript also inhibits CCK-induced gastric and gallbladder emptying in mice (ED50s = 3 and 72 μg/kg, respectively). Lintitript is also very active (ED50= 27 μg/kg p.o.) in the gall bladder emptying protocol with egg yolk as an inducer of endogenous CCK release[1]. | ||||||||||||||||
分子量 | 411.86 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H14ClN3O3S | ||||||||||||||||
CAS 号 | 136381-85-6 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(242.80 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |